Clinical Trial Update: X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for X-396 capsule in advanced non-small cell lung cancer with ROS1 gene rearrangement.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• X-396

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Lung Cancer, ROS1 Gene Rearrangement | Phase 2 | Status: UNKNOWN